Microneedles for treatment of peanut allergy

微针治疗花生过敏

基本信息

  • 批准号:
    10219057
  • 负责人:
  • 金额:
    $ 64.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-17 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

Microneedles for treatment of peanut allergy Peanut allergy is a life-threatening condition. About 1% of the US population (~3 million people) has peanut allergies, and there is no FDA-approved treatment. Strict avoidance, and a peanut-free diet is the only option available to manage peanut allergies, which imposes severe limitations on the lifestyle of the patient and their families, and can lead to nutritional deficiencies. The overall goal of this proposal is to develop a coated microneedles (MNs) based cutaneous immunotherapy (CIT) a.k.a (MNs-CIT) for peanut allergy. Presently peanut oral immunotherapy has received much attention. However, a major limitation of oral immunotherapy is that the peanut oral dose is escalated to thousands of milligrams, which causes adverse effects. Based on our preliminary data our hypothesis is that MNs coated with peanut allergen can safely deliver peanut allergen in to the superficial skin-layer to produce long-lasting peanut desensitization. Our specific aims are: (i) Develop PE- coated MNs and evaluate their short and long term therapeutic effectiveness in treating peanut allergy, (ii) Characterize the mechanism of peanut MNs-CIT, and (iii) Evaluate therapeutic efficacy in a neonatal pig model of peanut allergy. If successful, these studies will provide the foundation to support the development of a novel and safer peanut allergy immunotherapy treatment.
微针治疗花生过敏 花生过敏是一种危及生命的疾病。大约1%的美国人口(约300万人)种植花生 过敏,而且没有FDA批准的治疗方法。严格避免,不吃花生是唯一的选择 可用于管理花生过敏,这对患者和他们的生活方式施加了严格的限制 家庭,并可能导致营养不足。这项提议的总体目标是开发一种涂层 以微针(MNS)为基础的皮肤免疫疗法(CIT)(MNS-CIT)治疗花生过敏。目前 花生的口服免疫疗法受到了广泛的关注。然而,口服免疫疗法的一个主要限制是 花生的口服剂量上升到数千毫克,这会产生不良反应。基于我们的 初步数据我们的假设是,包裹花生变应原的MNS可以安全地将花生变应原输送到 花生皮表层可产生持久的花生脱敏效果。我们的具体目标是:(I)发展私募股权- 包衣MN及其治疗花生过敏的近远期疗效评价(II) 描述花生MNS-CIT的作用机制,并(Iii)在新生猪模型上评估治疗效果 花生过敏症。 如果成功,这些研究将为开发一种新的、更安全的花生提供基础 变态反应免疫疗法治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Harvinder Singh Gill其他文献

ASO Visual Abstract: Tumor-Infiltrating Lymphocytes (TILs) as a Biomarker of Abscopal Effect of Cryoablation in Breast Cancer—A Pilot Study
  • DOI:
    10.1245/s10434-021-11240-2
  • 发表时间:
    2022-01-25
  • 期刊:
  • 影响因子:
    3.500
  • 作者:
    Sonia Y. Khan;Michael W. Melkus;Fahmida Rasha;Maribel Castro;Victoria Chu;Luis Brandi;Hafiz Khan;Harvinder Singh Gill;Kevin Pruitt;Rakhshanda Layeequr Rahman
  • 通讯作者:
    Rakhshanda Layeequr Rahman

Harvinder Singh Gill的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Harvinder Singh Gill', 18)}}的其他基金

Development of a Universal Influenza Vaccine Against Influenza A and B Viruses
开发针对甲型和乙型流感病毒的通用流感疫苗
  • 批准号:
    10053298
  • 财政年份:
    2018
  • 资助金额:
    $ 64.98万
  • 项目类别:
Microneedles for treatment of peanut allergy
微针治疗花生过敏
  • 批准号:
    9662551
  • 财政年份:
    2018
  • 资助金额:
    $ 64.98万
  • 项目类别:
Development of a Universal Influenza Vaccine Against Influenza A and B Viruses
开发针对甲型和乙型流感病毒的通用流感疫苗
  • 批准号:
    10291415
  • 财政年份:
    2018
  • 资助金额:
    $ 64.98万
  • 项目类别:
Development of a Universal Influenza Vaccine Against Influenza A and B Viruses
开发针对甲型和乙型流感病毒的通用流感疫苗
  • 批准号:
    10519103
  • 财政年份:
    2018
  • 资助金额:
    $ 64.98万
  • 项目类别:
Microneedles for treatment of peanut allergy
微针治疗花生过敏
  • 批准号:
    10471226
  • 财政年份:
    2018
  • 资助金额:
    $ 64.98万
  • 项目类别:
Engineering an intranasal universal influenza vaccine
设计鼻内通用流感疫苗
  • 批准号:
    9526306
  • 财政年份:
    2017
  • 资助金额:
    $ 64.98万
  • 项目类别:
Nanoengineered virus-mimics as templates for design of a universal influenza A va
纳米工程病毒模拟物作为通用甲型流感病毒设计的模板
  • 批准号:
    8499243
  • 财政年份:
    2012
  • 资助金额:
    $ 64.98万
  • 项目类别:
Nanoengineered virus-mimics as templates for design of a universal influenza A va
纳米工程病毒模拟物作为通用甲型流感病毒设计的模板
  • 批准号:
    8285558
  • 财政年份:
    2012
  • 资助金额:
    $ 64.98万
  • 项目类别:
POLLEN GRAINS AS TROJAN HORSES FOR ORAL VACCINATION
花粉粒作为口服疫苗的特洛伊木马
  • 批准号:
    8356940
  • 财政年份:
    2012
  • 资助金额:
    $ 64.98万
  • 项目类别:
Targeting the oral cavity epithelium for inducing mucosal immunity against HIV
靶向口腔上皮诱导针对 HIV 的粘膜免疫
  • 批准号:
    8249376
  • 财政年份:
    2011
  • 资助金额:
    $ 64.98万
  • 项目类别:

相似海外基金

Immunological profiling of multi-food allergen immunotherapy assessing humoral and cellular activation profiles
多种食物过敏原免疫疗法的免疫学分析,评估体液和细胞激活情况
  • 批准号:
    449815
  • 财政年份:
    2020
  • 资助金额:
    $ 64.98万
  • 项目类别:
    Studentship Programs
Elucidation of mechanisms for induction of regulatory T cells by IgG1 that increase in allergen immunotherapy
阐明过敏原免疫治疗中增加的 IgG1 诱导调节性 T 细胞的机制
  • 批准号:
    19K16385
  • 财政年份:
    2019
  • 资助金额:
    $ 64.98万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The combination of allergen immunotherapy with anti-IL-4 receptor-alpha antibody (dupilumab) for induction of human allergen-specific tolerance
过敏原免疫疗法与抗 IL-4 受体-α 抗体(dupilumab)相结合,用于诱导人类过敏原特异性耐受
  • 批准号:
    MR/T00164X/1
  • 财政年份:
    2019
  • 资助金额:
    $ 64.98万
  • 项目类别:
    Fellowship
Identifying the mechanism of allergen immunotherapy using single cell and bulk gene expression information.
使用单细胞和大量基因表达信息识别过敏原免疫治疗的机制。
  • 批准号:
    19H03696
  • 财政年份:
    2019
  • 资助金额:
    $ 64.98万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Challenge for treatment of dog allergy by allergen immunotherapy using hypoallergenic vaccine
使用低过敏性疫苗进行过敏原免疫疗法治疗狗过敏的挑战
  • 批准号:
    17K19329
  • 财政年份:
    2017
  • 资助金额:
    $ 64.98万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Development of a Dissolving Film for Allergen Immunotherapy in Children
开发用于儿童过敏原免疫治疗的溶解膜
  • 批准号:
    8676849
  • 财政年份:
    2013
  • 资助金额:
    $ 64.98万
  • 项目类别:
Development of a Dissolving Film for Allergen Immunotherapy in Children
开发用于儿童过敏原免疫治疗的溶解膜
  • 批准号:
    8510886
  • 财政年份:
    2013
  • 资助金额:
    $ 64.98万
  • 项目类别:
Proof of concept study of combined allergen immunotherapy and antibiotics for the treatment of chronic atopic dermatitis
过敏原免疫疗法和抗生素联合治疗慢性特应性皮炎的概念验证研究
  • 批准号:
    G0701693/1
  • 财政年份:
    2009
  • 资助金额:
    $ 64.98万
  • 项目类别:
    Research Grant
ALLERGEN IMMUNOTHERAPY CO-ADMINISTERED WITH OMALIZUMAB, AN ANTI-IGE MAB
过敏原免疫疗法与 OMALIZUMAB(一种抗 IGE 单克隆抗体)联合使用
  • 批准号:
    7201329
  • 财政年份:
    2005
  • 资助金额:
    $ 64.98万
  • 项目类别:
Allergen Immunotherapy Co-Administered with Omalizumab
过敏原免疫疗法与奥马珠单抗联合给药
  • 批准号:
    7040810
  • 财政年份:
    2004
  • 资助金额:
    $ 64.98万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了